Study Reveals Infections as Leading Cause of Non-Relapse Deaths in CAR T-Cell Therapy Patients
New York, NY — Notwithstanding the therapeutic breakthroughs in CAR T-cell therapy for cancer treatment, recent research highlights concerning complications that can sometimes be lethal. This advanced form of immunotherapy, commonly utilized in combatting lymphoma and multiple myeloma, has shown remarkable efficacy, yet a segment of patients succumb not to their cancer, but to treatment-related complications, predominantly infections. The Memorial Sloan Kettering Cancer Center conducted a systematic review and meta-analysis recently that identified from a …